To learn more about the conference and see more talks like this please visit us at: https://www.leafscience.org/ending-age-related-diseases-2018/
As our organization grows and we are doing more and more things, there is an ever greater need for specialist knowledge and guidance to help inform our decisions as a company. We rely on the advice and expertize of both our scientific and business advisors and we have added to them this week with two new experts joining us.
We are delighted to announce that Steven A. Garan has joined our scientific advisory board. Steven is the Director of Bioinformatics at the Center for Research & Education on Aging (CREA) and serves on its advisory board, and he is a researcher at the Lawrence Berkeley National Laboratory. While at the University of California, Berkeley, he played a major role in the invention and the development of the Automated Imaging Microscope System (AIMS), and he collaborated for many years with a group from Paola S. Timiras’ lab, researching the role that caloric restriction plays in maintaining estrogen receptor-alpha and IGH-1 receptor immunoreactivity in various nuclei of the mouse hypothalamus.
Steven was also the director of the Aging Research Center and is a leading scientist in the field of aging research. His numerous publications include articles on systems biology, the effects of caloric restriction on the mouse hypothalamus, and the AIMS. He is best known for coining the word “Phenomics”, which was defined in “Phenomics: a new direction for the study of neuroendocrine aging”, an abstract published in the journal Experimental Gerontology.
Aging (Albany NY). 2018 Jul 19;10:1666–1681. doi: 10.18632/aging.101500.
Latorre E, Torregrossa R, Wood ME, Whiteman M, Harries LW.
1University of Exeter Medical School, University of Exeter, UK.2College of Life and Environmental Sciences, University of Exeter, UK.
#mTOR (mammalian target of rapamycin) Inhibiting TORC1 has been shown to increase lifespan.
Today, we are pleased to announce that the results are in from a human trial that targets the aging immune system and that an immune system-boosting drug appears to be effective.
Targeting TORC1 to boost the immune system
Continue reading “ResTORbio Announces Results in Phase 2b Human Trial” »
Dr. Aubrey de Grey gives his keynote speech at the Ending Age-Related Diseases 2018 conference in NYC. This was our first conference and we will be back every year from now on.
To learn more about the event check out the conference page here:
https://www.leafscience.org/ending-age-related-diseases-2018/
Today, we were pleased to hear that Samumed, a San Diego-based biotech company working on regenerative medicine, has just raised $438 million towards developing anti-aging therapies.
SAN DIEGO – August 6, 2018 – Samumed, LLC, announced today that it has closed its A-6 Round of equity issuance with $438 million, bringing its total equity raised to date to more than $650 million. The pre-money valuation for the round was $12 billion.
“We appreciate the strong support from our investors,” said Osman Kibar, Ph.D., Chief Executive Officer of Samumed, “and we are now in a fortunate position to both move our later stage programs to commercialization, as well as expand on our earlier stage science and clinical portfolio.”
Ichor Therapeutics, a life science company in Lafayette, New York, is one of the big players in the world of rejuvenation biotechnologies. Since its founding in 2013, it has been growing and expanding its portfolio of companies working on therapies against the diseases of aging; on August 1, 2018, Ichor announced the formation of its strategic fund, Grapeseed.bio.
What is Grapeseed.bio
This new fund and accelerator program is meant to provide young life science startups with seed funding up to $100,000, technical training, mentorship, and full access to Ichor’s large research laboratory.
Today, we wanted to draw your attention to a review of aging and the role that the gut microbiome plays in it.
There is an increasing amount of evidence for the contribution of microbial burden in the chronic, age-related background of inflammation known as “inflammaging”. There are a number of proposed sources of inflammaging, including senescent cells, immunosenescence, cell debris, and microbial burden.
We have delved into the topic of the gut microbiome in the past and its possible role as the origin point of inflammaging in a previous article, but we wanted to highlight this publication for people interested in reading further about this rapidly evolving area of aging research [1].
For centuries humans have sought the ‘elixir of life’ – a mythical potion that supposedly would grant the drinker eternal life.
Now Exeter scientists believe they may have found the secret to a longer, healthier life.
New compounds developed and tested at the University of Exeter have brought the dream a step closer and paved the way for “anti-degeneration” drugs that could not only extend life, but also extend health and may help treat age-related diseases like cancer, dementia and diabetes.
Continue reading “Exeter University boffins have discovered ‘elixir of life’” »
